SnET2 for Ophthalmology Sample Clauses

SnET2 for Ophthalmology. Unless otherwise determined by the parties, Miravant shall be responsible for conducting all necessary Preclinical Tests and Phase I and Phase II Clinical Tests for SnET2 to be used in any indications in the Field. The Out-of-Pocket Expenses associated with Preclinical Tests, Phase I and Phase II Clinical Tests being conducted by Miravant on the Effective Date, or conducted by Miravant thereafter, shall be reimbursed by P&U AB; provided, that these studies were conducted in accordance with the protocols and budget approved by the Operating Committee. Miravant shall be responsible for conducting Phase III Clinical Tests of SnET2 in the United States, and P&U AB shall reimburse Miravant for all Out of Pocket Expenses so incurred; provided, that these studies were conducted in accordance with the protocols and budgets approved by the Operating Committee. P&U AB will be responsible for conducting Phase III Clinical Tests of SnET2 in the rest of the world. P&U AB shall be responsible for conducting all post-NDA approval studies which may be necessary. The Operating Committee has the right to determine, in its reasonable judgment, whether to proceed to Phase III Clinical Tests for any indication in the Field. All Clinical Tests shall be conducted in accordance with the protocols approved by the Operating Committee. Miravant shall supply to P&U AB SnET2 and Light Devices to enable P&U AB to carry out such Phase III Clinical Tests conducted by it. The actual costs of SnET2 and Light Devices for all Clinical Test phases shall be shared equally by the parties hereto.
Sample 1
AutoNDA by SimpleDocs
SnET2 for Ophthalmology. Notwithstanding anything herein to the contrary, for Ophthalmology, unless otherwise determined by the Ophthalmology Operating Committee, PDTI shall be responsible for conducting all necessary Preclinical Tests and Phase I and Phase II Clinical Tests for SnET2 to be used in any Ophthalmology indications within the Fields. The Out-of-Pocket Expenses associated with Preclinical Tests, Phase I and Phase II Clinical Tests being conducted by PDT on the Ophthalmology Effective Date, or conducted by PDT thereafter, shall be refunded by Pharmacia, provided that these studies have been conducted in agreement with the Ophthalmology Operating Committee. Pharmacia shall be responsible for conducting and shall bear all costs associated with Phase III Clinical Tests of SnET2 to be used in all Ophthalmology indications, as well as for all post-NDA approval studies which may be necessary; provided, however, that the Ophthalmology Operating Committee has the right to determine, in its reasonable judgment, whether to proceed to Phase III Clinical Tests as to any Ophthalmology indication. PDTI shall supply to Pharmacia SnET2 and Light Devices to enable Pharmacia to carry out Phase III Clinical Tests required to support an NDA for SnET2. The actual costs of SnET2 and Light Devices for all Clinical Test phases shall be shared equally by the parties hereto."
Sample 1

Related to SnET2 for Ophthalmology

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Field The term “

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • For clarity Research Tools are subject to the license grants in Sections 2.1-2.3, Section 2.8, the retained rights set forth in Sections 2.9, and the due diligence requirements in Section 6.

  • Manufacturing Agreement Each of the Sellers (as applicable) shall have executed and delivered to the Buyer the Manufacturing Agreement with respect to the portion of the Business conducted at the applicable Facility.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!